A Randomized Phase II Pilot Study Prospectively Evaluating Treatment For Patients Based On Ercc1 (Excision Repair Cross-Complementing 1) For Advanced/
Posted Date: May 15, 2019
- Investigator: John Morris
- Type of Study: Drug
The purpose of this study is to find out what effects (good and bad) a targeted therapy approach has on esophageal, gastric, or gastroesophageal junction cancer. About 225 people will take part in this study with approximately 6 people participating locally.
Criteria:
Eligible Patients Must Have Advanced Esophageal, Gastric, Or Gastroesophageal Junction Cancer
Keywords:
Esophageal, Gastric, Gastrointestinal Can, Gej, S1201
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu